Department of
Internal Medicine at Highland Hospital
A member of Alameda Health System

Faculty


Return to Faculty List
C. Michael Neuwelt MD
Division: Rheumatology
Chief of Rheumatology

Medical School: The George Washington University Medical School

Residency: The George Washington University Medical School

Fellowship: The George Washington University Medical School

Clinical Interest: Systemic Lupus Erythematosus (SLE); Neuropsychiatric SLE; New Biological Treatments for SLE; Advisory Board of “Lupus Now” magazine of The Lupus Foundation of America - 2007 to present

Recent Publications:

Grand Rounds Presentation: Lupus Expert Awareness Program; Berlin, Germany; May 24, 2014

Recent Presentations:

Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, Neuwelt CM, Robbie G, White W, Yao Y, Wang L, Ethgen D, Greth W., et al. Sifalimumab, a Human Anti-Inferon-α Monoclonal Antibody, In Subjects with Systemic Lupus Erythematosus: Results of a Phase 1b Randomized, Placebo-Controlled, Dose-Escalation Study. Arthritis & Rheumatism. April 2014; 65 (4): 1011-21.

Wallace DJ, Ordi-Ros J., Neuwelt M. et al. Epratuzumab: Long-Term Safety and Efficacy on Corticosteroid Use. Ninth European Lupus Meeting April 2014. Sixteenth Asia Pacific League of Associates for Rheumatology Congress, March 2014.

Wallace DJ, Ordi-Ros J., Neuwelt M. et al. Epratuzumab: Sustained Safety Profile and Effect on Corticosteroid Use on Long-Term Treatment in Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open Label, Long-Term Extension Study (SL0008). European League Against Rheumatism (EULAR) 2013 Congress.

Wallace DJ, Ordi-Ros J., Neuwelt M. et al. Overview of Safety of Epratuzumab in Systemic Lupus Erythematosus. American College of Rheumatology Annual Scientific Meeting, San Diego, California, October 2013.

Sullivan, B., Tsuji, W., Chindalore, V.,  Geppert, T., Rudinskaya, A., Pardo, P., Kivitz, A., Neuwelt M. et al. Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE:  Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study. American College of Rheumatology, San Diego, California, October 2013